B. Rosen

B. Clarke, M. Bernardini, B. Rosen, 2017, Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC.

Teaching Cervical Cancer Surgery in Low- or Middle-Resource Countries

Dianne Miller, J. McAlpine, P. Cybulska, 2010, International Journal of Gynecologic Cancer.

Breast and ovarian cancer risk perception after prophylactic salpingo‐oophorectomy due to an inherited mutation in the BRCA1 or BRCA2 gene

B. Rosen, S. Narod, L. Elit, 2009, Clinical genetics.

Underdiagnosis of Hereditary Breast Cancer: Are Genetic Testing Guidelines a Tool or an Obstacle?

Rakesh R. Patel, R. Nussbaum, R. Simmons, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation.

B. Karlan, P. Møller, W. Foulkes, 2018, Gynecologic oncology.

Combined Adjuvant Chemotherapy and Radiation Therapy Improves Disease-Free Survival for Uterine Serous Cancer

B. Rosen, J. Field, H. Ye, 2020, Advances in radiation oncology.

The optimal organization of gynecologic oncology services: a systematic review.

R. McLeod, T. Colgan, D. D'Souza, 2015, Current oncology.

Organizational Guideline for Gynecologic Oncology Services in Ontario

R. McLeod, T. Colgan, B. Rosen, 2015 .

An Organizational Guideline for Gynecologic Oncology Services

R. McLeod, T. Colgan, D. D'Souza, 2015, International Journal of Gynecologic Cancer.

A triage assessment strategy for the management of women with endometrial cancer.

B. Clarke, M. Bernardini, B. Rosen, 2013, Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC.

Tamoxifen and the risk of ovarian cancer in BRCA1 mutation carriers.

C. Isaacs, J. Lubiński, N. Tung, 2009, Gynecologic Oncology.

A proteome resource of ovarian cancer ascites: integrated proteomic and bioinformatic analyses to identify putative biomarkers.

A. Ignatchenko, I. Jurisica, T. Kislinger, 2008, Journal of proteome research.

Hormone Therapy and the Risk of Breast Cancer in BRCA 1 Mutation Carriers

J. Klijn, P. Møller, G. Rennert, 2008 .

Occult Carcinoma in Prophylactic Oophorectomy Specimens: Prevalence and Association With BRCA Germline Mutation Status

B. Rosen, S. Narod, D. Cole, 2001, The American journal of surgical pathology.

Protocol Development for Ovarian Cancer Treatment in Kenya: A Brief Report

B. Rosen, M. Strother, L. V. van Lonkhuijzen, 2010, International Journal of Gynecologic Cancer.

Informatics and Ovarian Cancer Care

B. Rosen, L. Elit, P. Ghatage, 2009 .

long- t erm Ov arian cancer Sur vival Associated With Mutation in Brc A1 or B rc A2

T. Sellers, B. Rosen, H. Risch, 2012 .

Successes and challenges of establishing a cervical cancer screening and treatment program in western Kenya

B. Rosen, S. Cu-Uvin, M. Strother, 2014, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

The risks of breast and ovarian cancer associated with the Ashkenazi Jewish founder allele BRCA2 6174delT

W. Foulkes, S. Neuhausen, E. Friedman, 2021, Clinical genetics.

Does histology influence prognosis in patients with early‐stage cervical carcinoma?

B. Rosen, P. Shaw, D. Grisaru, 2001, Cancer.

Correlation between germline mutations in MMR genes and microsatellite instability in ovarian cancer specimens

T. Sellers, D. Coppola, Ji‐Hyun Lee, 2017, Familial Cancer.

The evolution of comprehensive cancer care in Western Kenya

B. Rosen, M. Krzyzanowska, G. Kaspers, 2013 .

Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis

W. Foulkes, N. Tung, B. Rosen, 2014, BMJ : British Medical Journal.

Risk of ipsilateral breast cancer in BRCA1 and BRCA2 mutation carriers

O. Olopade, W. Foulkes, N. Tung, 2011, Breast Cancer Research and Treatment.

Consolidative abdominopelvic radiotherapy after surgery and carboplatin/paclitaxel chemotherapy for epithelial ovarian cancer.

A. Oza, M. Lock, B. Rosen, 2002, International journal of radiation oncology, biology, physics.

Examining Survival Outcomes of 852 Women With Advanced Ovarian Cancer: A Multi-institutional Cohort Study

B. Rosen, J. McGee, Wei Xu, 2018, International Journal of Gynecologic Cancer.

A Comparison of Survival Outcomes in Advanced Serous Ovarian Cancer Patients Treated With Primary Debulking Surgery Versus Neoadjuvant Chemotherapy

B. Rosen, S. Narod, J. Kotsopoulos, 2017, International Journal of Gynecologic Cancer.

Epidemiologic factors that predict long-term survival following a diagnosis of epithelial ovarian cancer

B. Rosen, H. Risch, S. Narod, 2017, British Journal of Cancer.

Ten-year survival after epithelial ovarian cancer is not associated with BRCA mutation status.

B. Rosen, H. Risch, S. Narod, 2016, Gynecologic oncology.

Stage at diagnosis and ovarian cancer survival: evidence from the International Cancer Benchmarking Partnership.

M. Coleman, B. Rachet, N. Hacker, 2012, Gynecologic oncology.

TARGIT-R (Retrospective): North American Experience with Intraoperative Radiation Using Low-Kilovoltage X-Rays for Breast Cancer

B. Rosen, W. Small, A. Fyles, 2016, Annals of Surgical Oncology.

Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers

O. Olopade, W. Foulkes, N. Tung, 2011, British Journal of Cancer.

Health care use and risk of ovarian cancer: Is there a link?

B. Rosen, T. Oliver, M. Brouwers, 2007, Canadian Medical Association Journal.

Peritoneal lavage cytology: an assessment of its value during prophylactic oophorectomy.

T. Colgan, B. Rosen, S. Narod, 2002, Gynecologic oncology.

Implementation of Ovarian Cancer Surgery Guidelines

B. Rosen, L. Elit, D. Thiruchelvam, 2001 .

Laparoscopic Surgery for Endometrial Cancer

B. Rosen, W. Gotlieb, M. Plante, 2010 .

Breast and Ovarian Cancer: The Forgotten Paternal Contribution

C. Greenwood, B. Rosen, D. Chitayat, 2011, Journal of Genetic Counseling.

Risk factors for non-invasive lesions of the fallopian tube in BRCA mutation carriers.

B. Rosen, S. Narod, P. Shaw, 2010, Gynecologic oncology.

The Effectiveness of Family History Questionnaires in Cancer Genetic Counseling

B. Rosen, T. Panzarella, R. Demsky, 2009, Journal of Genetic Counseling.

Should hysterectomy complement prophylactic salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers?

B. Rosen, S. Narod, I. Vyarvelska, 2014, Gynecologic oncology.

Initial evaluation and referral guidelines for management of pelvic/ovarian masses.

B. Rosen, T. Le, S. Lau, 2009, Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC.

Kallikreins as Markers of Disseminated Tumour Cells in Ovarian Cancer – A Pilot Study

A. Scorilas, E. Diamandis, B. Rosen, 2006, Tumor Biology.

Anthropometric Measures and Risk of Ovarian Cancer Among BRCA1 and BRCA2 Mutation Carriers

B. Karlan, W. Foulkes, J. Lubiński, 2012, Obesity.

Hereditary and familial ovarian cancer in southern ontario

P. Tonin, B. Rosen, H. Risch, 1994, Cancer.

Incidental MRI detection of BRCA1-related solitary peritoneal carcinoma during breast screening--A case report.

B. Rosen, E. Warner, P. Shaw, 2007, Gynecologic oncology.

Development and testing of a decision aid for breast cancer prevention for women with a BRCA1 or BRCA2 mutation

B. Rosen, S. Narod, A. O'Connor, 2007, Clinical genetics.

Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.

O. Olopade, W. Foulkes, N. Tung, 2015, JAMA oncology.

Computational modeling of ovarian cancer dynamics suggests optimal strategies for therapy and screening

Myles A Brown, A. Oza, D. Levine, 2021, Proceedings of the National Academy of Sciences.

Psychological impact of screening for familial ovarian cancer: reactions to initial assessment.

B. Rosen, L. Bradley, D. Cole, 1997, Gynecologic oncology.

Commentary on "Accelerated partial breast irradiation consensus statement: Update of an ASTRO Evidence-Based Consensus Statement".

D. Holmes, B. Rosen, M. Baum, 2017, Practical radiation oncology.

Uptake of clinical genetic testing for ovarian cancer in Ontario: a population-based study.

B. Rosen, H. Risch, S. Narod, 2009, Gynecologic oncology.

Impact of germline mutations in cancer-predisposing genes on long-term survival in patients with epithelial ovarian cancer

B. Rosen, H. Risch, S. Narod, 2022, British Journal of Cancer.

Multicentre study on factors affecting the gynaecologic oncology career choice of canadian residents in obstetrics and gynaecology.

B. Rosen, S. Fung, J. Dodge, 2010, Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC.

The impact of oophorectomy on survival after breast cancer in BRCA1 and BRCA2 mutation carriers.

O. Olopade, W. Foulkes, N. Tung, 2014 .

How important is removal of the parametrium at surgery for carcinoma of the cervix?

T. Colgan, B. Rosen, P. Shaw, 2002, Gynecologic oncology.

The impacts of neoadjuvant chemotherapy and of cytoreductive surgery on 10‐year survival from advanced ovarian cancer

M. Bernardini, B. Rosen, S. Narod, 2020, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

Meta-analysis comparing cisplatin total dose intensity and survival.

T. Einarson, B. Rosen, E. Franssen, 1995, Gynecologic oncology.

Differences in the morbidity of radical hysterectomy between gynecological oncologists.

T. Colgan, B. Rosen, P. Shaw, 1993, Gynecologic oncology.

Surgical Outcome of Robotic Surgery in Morbidly Obese Patient With Endometrial Cancer Compared to Laparotomy

M. Bernardini, B. Rosen, L. Gien, 2012, International Journal of Gynecologic Cancer.

Clinical Utility of Universal Germline Genetic Testing for Patients With Breast Cancer

R. Simmons, H. Macdonald, D. Holmes, 2022, JAMA network open.

Concurrent radiation and chemotherapy in vulvar carcinoma.

B. Rosen, A. Fyles, I. Ackerman, 1989, Gynecologic oncology.

The Fallopian Tube: Primary Site of Most Pelvic High-grade Serous Carcinomas

D. Huntsman, M. Köbel, Dianne Miller, 2009, International Journal of Gynecologic Cancer.

Does aggressive therapy improve survival in suboptimal stage IIIc/IV ovarian cancer? A Canadian-American comparative study.

E. Franssen, B. Rosen, R. Buckman, 1995, Gynecologic oncology.

Hormone replacement therapy and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers.

B. Karlan, P. Møller, C. Isaacs, 2006, Gynecologic oncology.

Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada.

Barry Rosen, B. Rosen, H. Risch, 2006, Journal of the National Cancer Institute.

Risk factors for carcinoma of the fallopian tube in women with and without a germline BRCA mutation.

B. Karlan, B. Rosen, S. Narod, 2010, Gynecologic oncology.

Coffee consumption and breast cancer risk among BRCA1 and BRCA2 mutation carriers

Jan Lubinski, Charis Eng, Ping Sun, 2006, International journal of cancer.

Estimating survival rates after ovarian cancer among women tested for BRCA1 and BRCA2 mutations

A. Risch, B. Rosen, S. Narod, 2013, Clinical genetics.

The impacts of neoadjuvant chemotherapy and of debulking surgery on survival from advanced ovarian cancer.

Sarah Ferguson, Ping Sun, Barry Rosen, 2014, Gynecologic oncology.

Telomere Length and Mortality Following a Diagnosis of Ovarian Cancer

B. Rosen, H. Risch, S. Narod, 2014, Cancer Epidemiology, Biomarkers & Prevention.

A longitudinal study of psychological adjustment to familial genetic risk assessment for ovarian cancer.

Catharine Wang, B. Rosen, P. Ritvo, 1999, Gynecologic oncology.

Histopathologic score predicts recurrence free survival after radical surgery in patients with stage IA2–IB1–2 cervical carcinoma

T. Colgan, B. Rosen, P. Shaw, 2003, Cancer.

The effect of adjuvant radiation on survival in early stage clear cell ovarian carcinoma.

M. Bernardini, B. Rosen, G. Thomas, 2016, Gynecologic oncology.

Psychological side-effects of clomiphene citrate and human menopausal gonadotrophin

D. Stewart, B. Rosen, J. Irvine, 2005, Journal of psychosomatic obstetrics and gynaecology.

Epithelial‐Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk

Yurii B. Shvetsov, Lara E Sucheston-Campbell, Lara E. Sucheston-Campbell, 2015, Genetic epidemiology.

Systematic Review of Internet Patient Information on Colorectal Cancer Surgery

B. Rosen, N. Baxter, A. Halverson, 2014, Diseases of the colon and rectum.

Case Report: Use of Tumor and Germline Y Chromosomal Analysis to Guide Surgical Management in a 46, XX Female Presenting With Gonadoblastoma With Dysgerminoma.

A. Noor, T. Colgan, B. Rosen, 2017, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

Long-term outcomes following a diagnosis of ovarian cancer at the time of preventive oophorectomy among BRCA1 and BRCA2 mutation carriers

B. Karlan, P. Møller, W. Foulkes, 2020, International Journal of Gynecological Cancer.

High-resolution mapping of genomic imbalance and identification of gene expression profiles associated with differential chemotherapy response in serous epithelial ovarian cancer.

S. Minkin, M. Bernardini, B. Rosen, 2005, Neoplasia.

A model for estimating ovarian cancer risk: application for preventive oophorectomy.

J. Iqbal, B. Rosen, S. Narod, 2015, Gynecologic oncology.

The N314D polymorphism of galactose-1-phosphate uridyl transferase does not modify the risk of ovarian cancer.

B. Rosen, H. Risch, S. Narod, 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

Short Communication The N314D Polymorphism of Galactose-1-Phosphate Uridyl Transferase Does Not Modify the Risk of Ovarian Cancer

B. Rosen, H. Risch, S. Narod, 2003 .

The N 314 D Polymorphism of Galactose-1-Phosphate Uridyl Transferase Does Not Modify the Risk of Ovarian Cancer

B. Rosen, H. Risch, S. Narod, 2003 .

Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families

D. B. Berman, F. Couch, T. Rebbeck, 1996, Nature Medicine.

Differentially androgen-modulated genes in ovarian epithelial cells from BRCA mutation carriers and control patients predict ovarian cancer survival and disease progression

I Jurisica, I. Jurisica, B. Rosen, 2007, Oncogene.

Screening mammography and risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study.

P. Møller, W. Foulkes, C. Isaacs, 2006, The Lancet. Oncology.

Frequency of germline PALB2 mutations among women with epithelial ovarian cancer

B. Rosen, H. Risch, S. Narod, 2016, Familial Cancer.

Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer.

B. Rosen, L. Bradley, H. Risch, 2001, American journal of human genetics.

Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer.

Barry Rosen, B. Rosen, H. Risch, 2011, Gynecologic oncology.

Loss of coordinated androgen regulation in nonmalignant ovarian epithelial cells with BRCA1/2 mutations and ovarian cancer cells.

I. Jurisica, Mujahid Sultan, B. Rosen, 2003, Cancer research.

Targeted metabolomic profiling of low and high grade serous epithelial ovarian cancer tissues: a pilot study

D. Mutch, B. Rosen, A. Yilmaz, 2018, Metabolomics.

Genome-wide significant risk associations for mucinous ovarian carcinoma

Yurii B. Shvetsov, A. Whittemore, L. Kiemeney, 2015, Nature Genetics.

Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study

M. Beckmann, P. Fasching, R. Vierkant, 2014, British Journal of Cancer.

Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study.

A. Whittemore, R. Vierkant, M. García-Closas, 2013, The Lancet. Oncology.

A genetic epidemiological study of carcinoma of the fallopian tube.

B. Rosen, S. Narod, J. McLaughlin, 2001, Gynecologic oncology.

The incidence of leukaemia in women with BRCA1 and BRCA2 mutations: an International Prospective Cohort Study

Stephanie A Cohen, F. Couch, O. Olopade, 2016, British Journal of Cancer.

Incidence of colorectal cancer in BRCA1 and BRCA2 mutation carriers: results from a follow-up study

Charis Eng, Fergus Couch, Kevin Sweet, 2013, British Journal of Cancer.

Breast and ovarian cancer: Y do we forget about dad?

C. Greenwood, B. Rosen, D. Chitayat, 2010, The Lancet. Oncology.

High-Resolution Mapping of Genomic Imbalance and Identification of Gene Expression Profiles Associated with Differential Chemotherapy Response in Serous Epithelial Ovarian Cancer 1 *

S. Minkin, M. Bernardini, B. Rosen, 2005 .

Common Genetic Variation in Circadian Rhythm Genes and Risk of Epithelial Ovarian Cancer (EOC)

Dong Liang, Brooke L. Fridley, Jennifer A. Doherty, 2015, Journal of genetics and genome research.

Frequent somatic mutations of the telomerase reverse transcriptase promoter in ovarian clear cell carcinoma but not in other major types of gynaecological malignancy

B. Clarke, I. Shih, B. Rosen, 2014, The Journal of pathology.

Microarray expression identification of differentially expressed genes in serous epithelial ovarian cancer compared with bulk normal ovarian tissue and ovarian surface scrapings.

B. Rosen, Monique Albert, D. Grisaru, 2007, Oncology reports.

Sonographic Diagnosis of Primary Malignant Tumors of the Fallopian Tube

B. Rosen, Stephanie R. Wilson, M. Patlas, 2003, Ultrasound quarterly.

Circulating antibodies against p53 protein in patients with ovarian carcinoma

E. Diamandis, B. Rosen, K. Angelopoulou, 1996, Cancer.

Strengthening care and research for women's cancers in Sub-Saharan Africa

T. Rebbeck, E. Trimble, B. Rosen, 2017, Gynecologic oncology reports.

Pain Control in Breast Surgery: Survey of Current Practice and Recommendations for Optimizing Management—American Society of Breast Surgeons Opioid/Pain Control Workgroup

B. Rosen, T. James, E. S. Hwang, 2020, Annals of Surgical Oncology.

Network-Based Integration of GWAS and Gene Expression Identifies a HOX-Centric Network Associated with Serous Ovarian Cancer Risk

Dong Liang, Brooke L. Fridley, Jennifer A. Doherty, 2015, Cancer Epidemiology, Biomarkers & Prevention.

Effects of bilateral salpingo-oophorectomy on menopausal symptoms and sexual functioning among women with a BRCA1 or BRCA2 mutation.

B. Rosen, S. Narod, J. Kotsopoulos, 2019, Gynecologic oncology.

Keeping it simple: genetics referrals for all invasive serous ovarian cancers.

B. Rosen, M. Maganti, R. Demsky, 2013, Gynecologic oncology.

The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations. A prospective study.

P. Møller, J. Lubiński, E. Friedman, 2007, Gynecologic oncology.

Ovarian cancer survival by tumor dominance, a surrogate for site of origin

B. Rosen, H. Risch, S. Narod, 2015, Cancer Causes & Control.

Risk Factors for Ovarian Cancers With and Without Microsatellite Instability

T. Sellers, B. Rosen, H. Risch, 2014, International Journal of Gynecologic Cancer.

Risk Factors for Ovarian Cancers With and Without Microsatellite Instability

T. Sellers, B. Rosen, H. Risch, 2013, International Journal of Gynecologic Cancer.

Spontaneous and therapeutic abortions and the risk of breast cancer among BRCA mutation carriers

O. Olopade, B. Karlan, P. Møller, 2006, Breast Cancer Research.

International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers

Jan Lubinski, Fergus Couch, Ping Sun, 2008, International journal of cancer.

BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer.

D. Fishman, B. Karlan, J. Brunet, 2000, American journal of human genetics.

Gene Expression Profiles of Luteal Phase Fallopian Tube Epithelium from BRCA Mutation Carriers Resemble High-Grade Serous Carcinoma

B. Rosen, P. Shaw, A. Tone, 2008, Clinical Cancer Research.

Linkage analysis of 26 Canadian breast and breast-ovarian cancer families

N. Boyd, P. Tonin, J. Simard, 1995, Human Genetics.

The impact of prophylactic salpingo‐oophorectomy on quality of life and psychological distress in women with a BRCA mutation

B. Rosen, S. Narod, J. McLaughlin, 2013, Psycho-oncology.

Polymorphic Variation of Genes in the Fibrinolytic System and the Risk of Ovarian Cancer

B. Rosen, H. Risch, S. Narod, 2009, PloS one.

BRCA1 Mutation Status and Follicular Fluid Exposure Alters NFκB Signaling and ISGylation in Human Fallopian Tube Epithelial Cells12

T. Colgan, B. Rosen, C. Virtanen, 2018, Neoplasia.

Radical hysterectomy for operable early cervical cancer in HIV‐positive and HIV‐negative women in western Kenya

B. Rosen, Rachel N Deraney, S. Cu-Uvin, 2020, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility

Yurii B. Shvetsov, Lara E Sucheston-Campbell, A. Whittemore, 2018, PloS one.

Loss to Follow-Up in a Cervical Cancer Screening and Treatment Program in Western Kenya

B. Rosen, S. Cu-Uvin, P. Loehrer, 2018, Journal of Global Oncology.

Sequencing of Adjuvant Chemoradiation for Advanced Stage Endometrial Cancer

B. Rosen, J. Field, J. A. Rakowski, 2020, American journal of clinical oncology.

Outcomes After Salvage Radiation Therapy for Recurrent Endometrial Cancer in Patients With No Prior Adjuvant Therapy: An Institutional Review

B. Rosen, J. Field, H. Ye, 2020, Advances in radiation oncology.

Why have ovarian cancer mortality rates declined? Part I. Incidence.

J. Iqbal, B. Rosen, S. Narod, 2015, Gynecologic oncology.

Risk factors for endometrial cancer among women with a BRCA1 or BRCA2 mutation: a case control study

B. Karlan, P. Møller, J. Lubiński, 2015, Familial Cancer.

Toxicity and Efficacy After Adjuvant Vaginal Brachytherapy Using 30 Gy in 6 Fractions for Stages I and II Endometrial Cancer

B. Rosen, M. Almahariq, M. Jawad, 2021, Advances in Radiation Oncology.

Coexpression of hepatocyte growth factor-Met: an early step in ovarian carcinogenesis?

P. Leung, B. Rosen, N. Auersperg, 2001, Oncogene.

Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer

A. Whittemore, L. Kiemeney, M. Pike, 2015, Nature Communications.

All in the Family: Barriers and Motivators to the Use of Cancer Family History Questionnaires and the Impact on Attendance Rates

B. Rosen, M. Maganti, R. Demsky, 2015, Journal of Genetic Counseling.

Distinct patterns of structural and numerical chromosomal instability characterize sporadic ovarian cancer.

B. Rosen, J. Squire, J. Bayani, 2008, Neoplasia.

Molecular Profiling and Clinical Outcome of High-Grade Serous Ovarian Cancer Presenting with Low- versus High-Volume Ascites

B. Clarke, M. Bernardini, B. Rosen, 2014, BioMed research international.

Who should operate on patients with ovarian cancer? An evidence-based review.

B. Rosen, K. Kieser, J. Dodge, 2005, Gynecologic oncology.

Endometrial Cancer Risk Is Associated with Variants of the Mismatch Repair Genes MLH1 and MSH2

K. Siminovitch, B. Rosen, A. Fyles, 2006, Cancer Epidemiology Biomarkers & Prevention.

Treatment of infertility does not increase the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation.

B. Karlan, P. Møller, J. Lubiński, 2016, Fertility and sterility.

Low-Malignant-Potential Tumor of the Ovary: Sonographic Features With Clinicopathologic Correlation in 41 Patients

B. Rosen, Stephanie R. Wilson, Turki R Alfuhaid, 2003, Ultrasound quarterly.

Ovarian cancer risk is associated with a common variant in the promoter sequence of the mismatch repair gene MLH1.

K. Siminovitch, B. Rosen, H. Risch, 2008, Gynecologic oncology.

Height, weight, BMI and ovarian cancer survival.

B. Rosen, H. Risch, S. Narod, 2012, Gynecologic oncology.

Evaluation of an intraperitoneal chemotherapy program implemented at the Princess Margaret Hospital for patients with epithelial ovarian carcinoma.

H. Mackay, A. Oza, B. Rosen, 2009, Gynecologic oncology.

Low-grade and high-grade serous Mullerian carcinoma: review and analysis of publicly available gene expression profiles.

M. Birrer, V. Vathipadiekal, B. Rosen, 2013, Gynecologic oncology.

Genetic testing for BRCA1 and BRCA2 in the Province of Ontario

B. Rosen, A. Eisen, S. Narod, 2016, Clinical genetics.

The global cancer epidemic: opportunities for Canada in low- and middle-income countries

B. Rosen, S. Sutcliffe, M. Clemons, 2012, Canadian Medical Association Journal.

Constitutive and conditional cadherin expression in cultured human ovarian surface epithelium: Influence of family history of ovarian cancer

P. Leung, B. Rosen, N. Auersperg, 1999, International journal of cancer.

Laparoscopic surgery for endometrial cancer: a review.

B. Rosen, W. Gotlieb, M. Plante, 2010, Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC.

Giant hydropic uterine leiomyoma in pregnancy: unusual sonographic and Doppler appearance.

B. Rosen, S. Wilson, L. Moore, 1994, Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine.

Psychological adjustment to familial genetic risk assessment: differences in two longitudinal samples.

B. Rosen, P. Ritvo, R. Styra, 2000, Patient education and counseling.

Canadian Agency for Drugs and Technologies in Heath Liquid-Based Techniques for Cervical Cancer Screening : Systematic Review and Cost-Effectiveness Analysis

G. Tomlinson, A. Tricco, H. Witteman, 2008 .

The Use of Family History Questionnaires: An Examination of Genetic Risk Estimates and Genetic Testing Eligibility in the Non-responder Population

B. Rosen, R. Demsky, S. Armel, 2011, Journal of Genetic Counseling.

The use of transrectal ultrasound to biopsy pelvic masses in women.

B. Rosen, A. Toi, C. Giede, 2004, Gynecologic oncology.

Targeted metabolomic profiling of low and high grade serous epithelial ovarian cancer tissues: a pilot study

D. Mutch, B. Rosen, A. Yilmaz, 2018, Metabolomics.

The incidence of endometrial cancer in women with BRCA1 and BRCA2 mutations: an international prospective cohort study.

B. Karlan, P. Møller, W. Foulkes, 2013, Gynecologic oncology.

Risk of breast cancer after a diagnosis of ovarian cancer in BRCA mutation carriers: Is preventive mastectomy warranted?

B. Karlan, W. Foulkes, J. Lubiński, 2017, Gynecologic oncology.

Prognostic value of INPP4B protein immunohistochemistry in ovarian cancer.

L. Salmena, B. Rosen, H. Risch, 2015, European journal of gynaecological oncology.

Endometrioid Carcinoma of the Ovary: Outcomes Compared to Serous Carcinoma After 10 Years of Follow-Up.

B. Rosen, T. Panzarella, L. Gien, 2017, Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC.

Neoadjuvant chemotherapy and chemotherapy cycle number: A national multicentre study.

B. Rosen, J. McGee, Wei Xu, 2017, Gynecologic oncology.

Epidemiological profile and clinico-pathological features of pediatric gynecological cancers at Moi Teaching & Referral Hospital, Kenya

B. Rosen, A. Covens, Elkanah Omenge Orang'o, 2022, Gynecologic oncology reports.

The incidence of endometrial cancer in women with BRCA1 and BRCA2 mutations

J. Iqbal, B. Rosen, S. Narod, 2013 .

Decreasing incidence of cervical adenocarcinoma in Ontario: Is this related to improved endocervical Pap test sampling?

B. Rosen, L. Marrett, C. M. McLachlin, 2007, International journal of cancer.

Family history as a predictor of uptake of cancer preventive procedures by women with a BRCA1 or BRCA2 mutation

W. Foulkes, B. Rosen, A. Eisen, 2008, Clinical genetics.

Variation in rates of uptake of preventive options by Canadian women carrying the BRCA1 or BRCA2 genetic mutation

D. Horsman, W. Foulkes, B. Rosen, 2007, Open medicine : a peer-reviewed, independent, open-access journal.

Capacity building in sub-Saharan Africa: models of care

B. Rosen, J. Gralow, P. Loehrer, 2018 .

Development of a comprehensive and sustainable gynecologic oncology training program in western Kenya, a low resource setting

B. Rosen, A. Covens, L. V. van Lonkhuijzen, 2017, Gynecologic oncology reports.

The prognostic value of perioperative, pre‐systemic therapy CA125 levels in patients with high‐grade serous ovarian cancer

M. Bernardini, B. Rosen, S. Ferguson, 2018, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

Risk factors for endometrial cancer among women with a BRCA1 or BRCA2 mutation: a case control study

B. Karlan, P. Møller, J. Lubiński, 2015, Familial Cancer.

The optimal time for surgery in women with serous ovarian cancer.

M. Bernardini, B. Rosen, S. Ferguson, 2016, Canadian journal of surgery. Journal canadien de chirurgie.

Use of Palliative Cisplatinum for Advanced Cervical Cancer in a Resource-Poor Setting: A Case Series From Kenya

B. Rosen, L. V. van Lonkhuijzen, Elkanah Omenge Orang'o, 2016, Journal of global oncology.

Correlation of differential ascites volume with primary cytoreductive surgery outcome, lymph node involvement, and disease recurrence in advanced ovarian cancer

B. Rosen, C. Massey, T. May, 2019, International Journal of Gynecological Cancer.

Adenocarcinoma involving the uterine cervix: magnetic resonance imaging findings in tumours of endometrial, compared with cervical, origin.

M. Haider, B. Rosen, K. Jhaveri, 2006, Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes.

Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer

Yurii B. Shvetsov, A. Whittemore, L. Kiemeney, 2015, Nature Communications.

Genome-wide significant risk associations for mucinous ovarian carcinoma

Yurii B. Shvetsov, A. Whittemore, L. Kiemeney, 2015, Nature Genetics.

Intraperitoneal chemotherapy for patients with advanced ovarian cancer: a review of the evidence and standards for the delivery of care.

D. Provencher, B. Rosen, T. Oliver, 2007, Gynecologic oncology.

A comparison of the toxicity and tolerability of two intraperitoneal chemotherapy regimens for advanced-stage epithelial ovarian cancer.

B. Rosen, S. Ferguson, L. Gien, 2016, Gynecologic oncology.

Preventing ovarian cancer through genetic testing: a population‐based study

B. Rosen, H. Risch, S. Narod, 2014, Clinical Genetics.

Patients' preferences for therapy in advanced epithelial ovarian cancer: development, testing, and application of a bedside decision instrument.

D. Streiner, A. Gafni, T. Whelan, 1996, Gynecologic oncology.

Stage at diagnosis and ovarian cancer survival: evidence from the International Cancer Benchmarking Partnership.

M. Coleman, B. Rachet, N. Hacker, 2012, Gynecologic oncology.

Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation.

B. Karlan, P. Møller, W. Foulkes, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Common Genetic Variation in Circadian Rhythm Genes and Risk of Epithelial Ovarian Cancer (EOC)

Yurii B. Shvetsov, Lara E Sucheston-Campbell, A. Whittemore, 2015, Journal of genetics and genome research.

Identification of six new susceptibility loci for invasive epithelial ovarian cancer

Yurii B. Shvetsov, Simon G. Coetzee, Dennis J. Hazelett, 2014, Nature Genetics.